The Powering Breast Cancer Progress grant programme, in collaboration with the Charities Aid Foundation (CAF), is focused on expanding patient navigation services to underserved populations across the globe. We have received and are currently reviewing applications from more than 50 countries, reinforcing that underserved patient populations exist across all economies. We look forward to announcing the grant awardees later this year. #PatientNavigation #BreastCancerSupport
AstraZeneca
Pharmaceutical Manufacturing
Cambridge, Cambridgeshire 2,959,512 followers
What science can do
About us
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
- Website
-
http://www.astrazeneca.com
External link for AstraZeneca
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Cambridge, Cambridgeshire
- Type
- Public Company
- Specialties
- Pharmaceutical, Biopharmaceutical, Innovation, Research and development, and Global business
Locations
-
Primary
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, Cambridgeshire CB2 0AA, GB
-
Astraallen
Sodertalje, Stockholm County 152 57, SE
Employees at AstraZeneca
Updates
-
Our Centre for Genomics Research is at the forefront of multi-omic innovation - leveraging bioinformatic, machine learning, and AI approaches to decode disease biology. Discover more about multi-omics in drug discovery and how we harness insights to better understand and develop treatments for complex diseases in this article from Drug Discovery World: https://learn.az/6046cCj9m
-
-
As a part of our focus on Sustainability, we responded to the US President's Emergency Plan for Adaptation and Resilience (PREPARE) with a commitment to help health systems across Africa adapt to the climate crisis. Pam Cheng, our EVP, Global Operations & IT and Chief Sustainability Officer, joined US government and business leaders to share how Healthy Heart Africa is supporting health system resilience in the face of climate change. Through the expansion of our flagship Healthy Heart Africa programme in nine countries, we will work with global and local partners to strengthen health systems so that they can address the health impacts of climate change, with a focus on heart and kidney diseases. Explore how we’re taking action: https://learn.az/6046cNRHs
-
-
We’ve announced our H1 and Q2 results, with the strength of our underlying business providing confidence to upgrade our full-year 2024 guidance. Total Revenue and Core EPS are now anticipated to grow by a mid teens percentage at CER. Thank you to the AstraZeneca team around the world who continue to unlock the power of what science can do for people, society and the planet. #AZN #WhatScienceCanDo
-
We will share our H1/Q2 2024 performance update at 07:00 BST on Thursday 25 July 2024. An accompanying webcast for investors and analysts will take place at 11:45 BST – you can register to attend here: https://lnkd.in/eXbAqb4R
This content isn’t available here
Access this content and more in the LinkedIn app
-
Through our partnership with the WEF EDISON Alliance, we committed to screen 5 million patients through AI-assisted chest X-rays that enable us to optimise and increase lung cancer screening and early detection. By the middle of June this year, we reached the milestone of 2.5 million AI-assisted chest X-rays scans across the world, with our partner Qure.ai and healthcare institutions around the world. While this is a noteworthy milestone to commemorate, a lot more needs to be done to drive a shift towards Lung Cancer detection at earlier stages, hence improving the chance for survival. We call upon on the global oncology community to come together, in a concerted effort to close the Lung Cancer care gap by making Screening & Early Detection a priority.
-
-
Our recent publication in JAMA Surgery written in partnership with Vestfold Hospital Trust and Universitetet i Oslo (UiO), shares new findings that demonstrate additional clinically meaningful impact on plasma lipid levels as a result of gastric bypass surgery as compared to matching weight loss without surgery. These findings provide new insights into the effects on cardiovascular (CV) risk factors during gastric bypass surgery and cardiometabolic benefits associated with weight management. Learn more here: https://learn.az/6043ieoEh
-
-
This World Youth Skills Day, we want to recognise the young leaders and advocates around the world who are forging a healthier future within their communities. Through our Young Health Programme, we are creating a global youth health movement led by, and for, young people. By providing opportunities for their leadership development, scholarships, and funding, we can help develop and empower the next generation of change-makers in communities around the world. Learn more: https://learn.az/6045iuTKl #WorldYouthSkillsDay #YoungHealthProgramme
-
Intended for investors: Today, we’re pleased to announce the completion of AstraZeneca’s acquisition of Amolyt Pharma, a global biopharmaceutical company specialising in rare endocrine and related diseases. This acquisition bolsters the Alexion, AstraZeneca Rare Disease pipeline and enables us to reach more patients living with #RareDiseases. Read more: https://learn.az/6042iOVpM
-
-
As our research uncovers more subtypes and personalised treatments, clear communication about biomarkers with patients is increasingly crucial. Our global survey with ABC Global Alliance emphasises the need to empower people living with metastatic breast cancer with knowledge about biomarkers to engage in their care decisions. To learn more visit: https://learn.az/6048gBOaY
-